2019

1. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

   Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125

2. Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

   Scientific Reports, Vol. 9, Núm. 1